AlloVir, Inc. (ALVR)
| Market Cap | 2.63B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 40.47M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $38.95 |
| Previous Close | $41.91 |
| Change ($) | -2.96 |
| Change (%) | -7.06% |
| Day's Open | 42.04 |
| Day's Range | 37.55 - 42.04 |
| Day's Volume | 273,457 |
| 52-Week Range | 21.05 - 46.81 |
The US IPO market is expected to remain active in the week ahead with eight IPOs slated to raise $4.6 billion. Street research is expected for Medirom Healthcare Technologies on Monday, 1/25.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one po...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Mo...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared t...
--(BUSINESS WIRE)--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely we...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS s...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthca...
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations tha...
Findings Demonstrate Significantly Higher Health Care Costs, Health Resource Utilization, and Worse Clinical Outcomes Among Allo-HCT Patients with Viral Infections Findings Demonstrate Signifi...
- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients
Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept Trials Appointment Expands AlloVir’s Regulatory Expertise as Company Plans...
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30...
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley ...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.
Stock of virus therapy biotech up more than 70% in just a few days
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offeri...
AlloVir Inc. said Thursday that its upsized initial public offering priced at $17 a share, in the middle of the expected range of $16 to $18 a share.
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offeri...
About ALVR
Allovir, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human me... [Read more...]
| Industry Biotechnology | IPO Date Jul 30, 2020 |
| CEO David L. Hallal | Employees 32 |
| Stock Exchange NASDAQ | Ticker Symbol ALVR |
Financial Performance
In 2019, AlloVir's revenue was $165,000, a decrease of -85.46% compared to the previous year's $1.14 million. Losses were -$23.84 million, 881.0% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for AlloVir stock is "Buy." The 12-month stock price forecast is 46.50, which is an increase of 19.38% from the latest price.